Drug intelligence / Profile preview

SSR97225

Development stage: Discontinued
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

SSR97225 is a small molecule tubulin-binding agent that acts as a tubulin inhibitor. It was developed by Sanofi for the treatment of solid tumors and refractory cancers. The drug works by binding to tubulin, arresting the cell cycle at the G2/M checkpoint, and preventing mitosis, thereby inhibiting cancer cell proliferation[1][2][3]. Clinical development reached Phase 1 trials in patients with refractory solid tumors but was discontinued before further advancement[2][3][8].

Other names: SSR97225SSR-97225SSR 97225

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SSR97225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSR97225.

Explore the full profile